Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/21/2025

Management of Patients Taking Rituximab

Introduction to Rituximab Therapy

  • Rituximab is used to treat various conditions, including rheumatoid arthritis and ANCA-associated vasculitis, with guidelines for its use provided by organizations such as the American College of Rheumatology 1, 2, 3

Guideline Recommendations for Laboratory Monitoring

  • The American College of Rheumatology guidelines do not recommend routine lipid profile monitoring in patients taking rituximab for rheumatoid arthritis and ANCA-associated vasculitis, instead focusing on hepatitis B screening, complete blood counts, and immunoglobulin levels 1, 2, 3
  • The Department of Veterans Affairs and Department of Defense guidelines state that routine lipid monitoring is not recommended once a statin is initiated, as statin efficacy is based on target dose rather than lipid levels 4
  • The KDIGO guidelines suggest that follow-up measurement of lipid levels should be reserved for instances where the results would alter management, particularly in patients with chronic kidney disease 5

Special Considerations for Patient Monitoring

  • Lipid testing might be considered in patients on rituximab with pre-existing cardiovascular disease, multiple cardiovascular risk factors, or as part of routine cardiovascular risk assessment independent of rituximab therapy 1, 2, 3
  • Patients with rheumatologic conditions may require additional monitoring of renal function, as recommended by the National Kidney Foundation 6

Hepatitis B Screening and Monitoring

  • Hepatitis B virus screening should include HBsAg, Anti-HBc, and HBV DNA if either test is positive, as recommended by the American Association for the Study of Liver Diseases 7, 8, 9
  • Failure to screen for hepatitis B before initiation can lead to potentially fatal HBV reactivation, emphasizing the importance of screening as per guidelines from the American Association for the Study of Liver Diseases 8, 9
  • For HBsAg-positive patients or those with past HBV infection receiving rituximab, HBV DNA levels should be monitored every 1-3 months during treatment and continued for 12 months after cessation of therapy, as recommended by the American Association for the Study of Liver Diseases and the American Society of Clinical Oncology 8, 9

Complete Blood Count Monitoring

  • Complete blood count (CBC) with differential should be monitored every 2-4 months during rituximab treatment, and continued for 6-12 months after completion of therapy, as suggested by the American College of Rheumatology 7
  • Special attention should be paid to platelet counts in patients with immune thrombocytopenia (ITP) during CBC monitoring, according to the American Society of Hematology 10

Immunoglobulin Level Monitoring

  • Immunoglobulin levels (IgG, IgM, IgA) should be monitored every 6 months during rituximab treatment, particularly in patients receiving multiple courses, as low baseline IgG levels can predict a greater risk of secondary immunodeficiency, although specific guidelines may vary 7, 11
  • The American College of Rheumatology recommends checking IgG, IgM, and IgA levels at baseline and every 6 months for patients treated with rituximab, as low baseline IgG level (<3 g/L) may predict greater risk of secondary immunodeficiency 11

Post-Treatment Monitoring and Complications

  • Inadequate post-treatment monitoring, especially in patients who received anti-CD20 therapy, can lead to overlooking potential complications, highlighting the need for monitoring for at least 12 months after completion, as suggested by the American Society of Clinical Oncology 9
  • Clinicians should maintain clinical vigilance for progressive multifocal leukoencephalopathy (PML) and consider the need for PJP prophylaxis with trimethoprim-sulfamethoxazole for 6 months following rituximab induction in certain conditions, although specific guidelines may vary 7
  • The Kidney International guideline suggests considering pneumocystis pneumonia prophylaxis with trimethoprim-sulfamethoxazole for 6 months following rituximab induction 11

Use of Intravenous Immunoglobulin (IVIG)

  • IVIG can be administered to patients on rituximab, but timing is critical - IVIG should be given when the next rituximab dose is due, and then rituximab should be held for at least 2 weeks after IVIG administration to maintain efficacy, as recommended by the American College of Rheumatology 12
  • Typical IVIG doses include:

    Indication Dose
    Treatment of inflammatory conditions 2 g/kg (typically divided as 0.4 g/kg/day for 5 days)
    Immunoglobulin replacement 400-800 mg/kg/month

    3, 13

  • Patients on IVIG and rituximab should be monitored for infusion reactions (headache, fever, chills) and rare but serious complications like transfusion-related acute lung injury (TRALI), and cardiac function and fluid status should be checked before IVIG administration, especially in patients with cardiac dysfunction 14

Vaccination Guidelines

  • Inactivated vaccines can be administered at any time before or after IVIG, as per the Arthritis care & research guideline 12
  • Live attenuated vaccines should be deferred for specific periods after IVIG:

    Indication Dose Wait Time
    IVIG 300-400 mg/kg 8 months
    IVIG 1 g/kg 10 months
    IVIG 2 g/kg 11 months, as recommended by the Arthritis and Rheumatology guideline [15]

REFERENCES

13

Inflammatory Neuropathy Treatment Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025